Analyst firms · Wells Fargo · STRO

Wells Fargo STRO price target and rating history

Sutro Biopharma Inc. (STRO) · Health Care

Wells Fargo rates Sutro Biopharma Inc. (STRO) Overweight with a $49 price target, as of its latest action on Sep 30, 2026. It has published 4 rating actions on STRO since August 2022, including 1 upgrade and 1 downgrade. Across 9 firms with a STRO price target in the last 12 months, the median target is $49. Wells Fargo's target matches it.

Current rating
Overweight
Price target
$49
Median target, all firms
$49
Actions on STRO
4

Wells Fargo price target on STRO

$49$29$82023202420252026
Wells Fargo price target on STRO, each point a stated target, August 2022 to September 2026.

Every Wells Fargo rating on STRO

How other firms rate STRO

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Wells FargoOverweight$49Sep 30, 2026
StifelBuy$48Aug 7, 2026
Truist SecuritiesBuy$50Jun 11, 2026
BarclaysOverweight$56May 28, 2026
WedbushOutperform$60May 15, 2026
MizuhoOutperform$50Apr 30, 2026
Leerink PartnersOutperform$38Apr 7, 2026
H.C. WainwrightBuy$28Mar 24, 2026
Citizens JMPMkt Outperform$23Jan 20, 2026

Questions about Wells Fargo and STRO

What is Wells Fargo's price target for STRO?
Wells Fargo's latest stated price target for Sutro Biopharma Inc. (STRO) is $49, from its action on Sep 30, 2026.
What is Wells Fargo's rating on STRO?
Wells Fargo rates STRO Overweight, a bullish rating, as of Sep 30, 2026.
When did Wells Fargo last change its view on STRO?
On Sep 30, 2026, Wells Fargo resumes coverage at Overweight, price target $49.
How does Wells Fargo's STRO target compare with other analysts?
Across 9 firms with a STRO price target in the last 12 months, the median target is $49. Wells Fargo's target matches it.

All Wells Fargo ratingsSTRO news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.